Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) have earned an average recommendation of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.00.Get Gyre Therapeutics alerts:GYRE has been the topic of several research reports. Zacks Research raised shares of Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, November 14th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Gyre Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Gyre Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, November 15th. Finally, Jefferies Financial Group assumed coverage on Gyre Therapeutics in a research report on Friday, October 10th. They set a "buy" rating and a $16.00 price objective on the stock.Read Our Latest Stock Analysis on GYREGyre Therapeutics Stock Down 3.5%NASDAQ:GYRE opened at $6.81 on Friday. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $13.75. The stock's 50-day simple moving average is $7.60 and its 200 day simple moving average is $7.65. The firm has a market capitalization of $656.01 million, a PE ratio of 227.08 and a beta of 1.99. Institutional Investors Weigh In On Gyre TherapeuticsSeveral hedge funds have recently added to or reduced their stakes in GYRE. State of Alaska Department of Revenue bought a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $38,000. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase & Co. grew its position in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in Gyre Therapeutics during the 3rd quarter valued at approximately $111,000. 23.99% of the stock is currently owned by institutional investors and hedge funds. Gyre Therapeutics Company Profile (Get Free Report)Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells. Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.Recommended StoriesFive stocks we like better than Gyre TherapeuticsA month before the crashDo not delete, read immediatelyA Message From An Ex-CIA Officer About TrumpHow a Family Trust May Be Able To Help Preserve Your WealthMarket Panic: Trump Just Dropped a Bomb on Your StocksThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Gyre Therapeutics Right Now?Before you consider Gyre Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here